Angiogenesis Inhibitors: all 4,430 studies that test it
Page 5 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingNCT05651932Phase 1
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)RecruitingNCT05642572Phase 2
- Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line TherapyRecruitingNCT05640830Phase 1/2
- Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) PatientsRecruitingNCT05638451Phase 2
- Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian CancerRecruitingNCT05636111Phase 1
- Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-riskRecruitingNCT05620771Phase 2
- Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular CarcinomaRecruitingNCT05616390Phase 2
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLRecruitingNCT05615636Phase 2
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2
- Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver MetastasesRecruitingNCT05588388Phase 2
- Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver MetastasesNot yet recruitingNCT05588297Phase 2
- A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyRecruitingNCT05585281Phase 2
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple MyelomaRecruitingNCT05583617Phase 1/2
- Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSLRecruitingNCT05583071Phase 2
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide RefractoryNot yet recruitingNCT05581875Phase 1/2
- Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT05575973Phase 2
- A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple MyelomaRecruitingNCT05573802Phase 1/2
- Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCLRecruitingNCT05552937Phase 2
- Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent GlioblastomaNot yet recruitingNCT05540275Phase 2
- Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast CancerRecruitingNCT05525767Phase 4
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingNCT05519085Phase 3
- Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse AstrocytomaNot yet recruitingNCT05518994Phase 2
- Radiotherapy Combined With Endostatin and Capecitabine for NPCRecruitingNCT05514275Phase 2
- Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse OligodendrogliomaRecruitingNCT05512351Phase 2
- Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung AdenocarcinomaRecruitingNCT05503667Phase 2
- Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse GlioblastomaNot yet recruitingNCT05502991Phase 2
- Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor PatientsRecruitingNCT05468359Phase 1/2
- Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation TherapyRecruitingNCT05468242Phase 2
- Lenalidomide in the Treatment of Mucosal Behçet's SyndromeRecruitingNCT05449548Not applicable
- A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical CancerNot yet recruitingNCT05444374Phase 2
- The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.RecruitingNCT05428670Phase 2
- Selinexor Plus VRd in High Risk Newly Diagnosed Multiple MyelomaRecruitingNCT05422027Phase 1/2
- Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast CancerRecruitingNCT05398861Phase 2
- Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSLRecruitingNCT05390749Phase 2
- Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasRecruitingNCT05389423Phase 1
- Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple MyelomaRecruitingNCT05378971Not applicable
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GISTRecruitingNCT05366816Phase 2
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerRecruitingNCT05365581Phase 1
- Tafasitamab Plus Lenalidomide in Relapsed CNS LymphomaRecruitingNCT05351593Phase 1/2
- Genotype-guided Treatment in DLBCLRecruitingNCT05351346Phase 3
- Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
- Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple MyelomaRecruitingNCT05344833Phase 2
- PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT05341193Phase 1/2
- Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNARecruitingNCT05334277Phase 2
- Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain InjuryRecruitingNCT05303259Phase 2
- A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome InhibitorNot yet recruitingNCT05298683Phase 2
- Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyEnrolling by invitationNCT05296447Phase 2
- Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent GlioblastomaRecruitingNCT05284643Not applicable
- Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung CancerRecruitingNCT05284539Phase 2
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant IneligibleRecruitingNCT05280275Phase 1/2
- Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBMRecruitingNCT05271240Phase 3
- Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System LymphomaRecruitingNCT05260619Phase 2
- Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary PlasmacytomaRecruitingNCT05248633Phase 2
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Phase 3
- Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDEnrolling by invitationNCT05210803Phase 2
- Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk MyelomaRecruitingNCT05208307Phase 2
- Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLCRecruitingNCT05203276Phase 2
- Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCLNot yet recruitingNCT05186558Phase 2
- Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan CriteriaEnrolling by invitationNCT05185505Phase 4
- Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell LymphomaRecruitingNCT05182957Phase 2
- Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal CarcinomaRecruitingNCT05177237Phase 2
- Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT05145400Phase 2
- Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During OperationRecruitingNCT05138029Phase 3
- Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course RadiotherapyRecruitingNCT05111860Phase 1/2
- Atezolizumab+Bevacizumab+SBRT in Unresectable HCCRecruitingNCT05096715Phase 1
- Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT05091372Phase 2
- ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver MetastasesRecruitingNCT05062317Phase 2
- IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsRecruitingNCT05039801Phase 1
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Phase 1/2
- Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian CancerRecruitingNCT05009082Phase 3
- Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanRecruitingNCT05005403Phase 1
- Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLCNot yet recruitingNCT04988607Phase 2
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerRecruitingNCT04981509Phase 2
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Phase 1/2
- Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung CancerRecruitingNCT04973293Not applicable
- Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMMRecruitingNCT04941937Phase 2
- Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS LymphomaRecruitingNCT04938297Phase 2
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingNCT04929223Phase 1
- Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell LymphomaRecruitingNCT04922567Phase 2
- APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant EffusionRecruitingNCT04919629Phase 2
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04910568Phase 1
- Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVRecruitingNCT04902443Phase 1
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)RecruitingNCT04853251Phase 4
- Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaRecruitingNCT04822337Phase 1/2
- Plasma Biomarker for Aflibercept in Advanced Colorectal CancerRecruitingNCT04810585Phase 4
- The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular CarcinomaRecruitingNCT04803994Phase 3
- Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone LymphomaRecruitingNCT04792502Phase 2
- A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian CancerRecruitingNCT04787289Phase 2
- Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast CancerRecruitingNCT04739670Phase 2
- Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System LymphomaRecruitingNCT04737889Phase 2
- 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.RecruitingNCT04689347Phase 1/2
- A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin LymphomaRecruitingNCT04669171Phase 1/2
- Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®RecruitingNCT04667039Phase 3
- A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingNCT04661137Phase 2
- Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal CancerRecruitingNCT04659382Phase 2
- Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.RecruitingNCT04627753Phase 2
- Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.RecruitingNCT04519476Phase 1
- A Study of Azenosertib (ZN-c3) in Patients With Ovarian CancerRecruitingNCT04516447Phase 1
- Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaRecruitingNCT04508790Phase 2
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingNCT04486352Phase 1/2